The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•30 April 2026•

1 min read

JP Morgan Maintains Underweight Rating on GSK with £17 Price Target

Key Facts

1JP Morgan retained its 'underweight' rating on GSK PLC with a June 2027 price target of £17.

2The bank sits 5-10% below consensus on core earnings for GSK starting from 2027.

JP Morgan has maintained its 'underweight' rating on GSK PLC, setting a price target of £17 through June 2027. Analyst Zain Ebrahim noted that the bank's core earnings projections for 2027 sit approximately 5% to 10% below the current market consensus. The financial institution believes GSK's long-term outlook remains heavily contingent on the successful execution of new product launches and the strength of its clinical pipeline. Furthermore, the report highlights limited potential for near-term earnings upgrades, which may constrain the stock's performance relative to its peers. This cautious stance persists despite modest adjustments to profit estimates, as concerns regarding long-term earnings sustainability remain at the forefront. Overall, the assessment reflects a conservative view of the pharmaceutical giant's ability to deliver market-beating financial growth in the coming years.